PanBRCA™ Inherited Breast & Ovarian Cancer Screening Test

Breast cancer - is the No.3 Killer in Hong Kong

Breast cancer is the THIRD most deadly cancer among women in Hong Kong, second only to lung cancer and colorectal cancer.
In 2018, a total of 753 women died of breast cancer, accounting for 12.4% of female cancer deaths.
Breast cancer also happens occasionally in men.
ccording to the latest 2020 study, it is estimated that more than 5 million people in China carry BRCA disease-causing gene mutations.
In Asians, the risk of a cancer-causing mutation in the BRCA gene represent as below:
87% of Breast cancer
44% of ovarian cancer and also an increased the risk for other types of cancer (such as pancreatic cancer, colorectal cancer, prostate cancer etc.)

Specifically designed for Asians - common Asian-specific gene mutations

Using next-generation sequencing (NGS) and the most advanced technology to detect any genetic mutations, including gene rearrangements and large deletions of BRCA1&2 genes, related to hereditary breast cancer and ovarian cancer.
PANGENIA's Breast Cancer and Ovarian Cancer Screening (BRCA1&2) is designed for screening Asian genetic mutations, with a coverage up to 95%.

PanBRCA™ Screening Test Features

Suitable For:

Early onset breast cancer(<45years old)
Bilateral or multiple primary breast cancers
Male breast cancer at any age
Breast and ovarian cancer in the same women
3 or more cases of breast cancer in the family
3 or more cases of breast, ovarian and/or pancreatic cancer in the family
3 or more cases of breast, uterine and/or thyroid cancer in the family
Multiple close family members with breast and other cancers

Test Specifications

Test Code Methodology Specimen Requirements Turnaround Time
OBS NGS (Next Generation Sequencing) 6ml blood in Lavender-top EDTA tube /
10 Buccal Swabs
4-6 Weeks
Multiplex ligation-dependent probe amplification (MLPA)